Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study

Abstract

Purpose

Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC).

Methods

This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS).

Results

The median sorafenib concentration was 2.91 μg/mL (range 0.74–8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54–0.93; p <0.05] and 1.40 μg/mL (AUC 0.97, 95% CI 0.97–1.00; p <0.05), respectively. OS of patients with sorafenib 1.40–3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40–3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)].

Conclusions

From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40–3.45 μg/mL in patients with HCC.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    CAS  Article  Google Scholar 

  2. 2.

    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    CAS  Article  Google Scholar 

  3. 3.

    Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR (2018) Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev 68:16–24

    CAS  Article  Google Scholar 

  4. 4.

    Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L et al (2018) Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers? World J Gastroenterol 24:4152–4163

    CAS  Article  Google Scholar 

  5. 5.

    Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P (2017) Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J Clin Oncol 35:622–628

    Article  Google Scholar 

  6. 6.

    Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J (2017) Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 67:999–1008

    CAS  Article  Google Scholar 

  7. 7.

    McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A et al (2018) Sorafenib as first-line therapy in patients with advanced Child–Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 105:1–9

    CAS  Article  Google Scholar 

  8. 8.

    Terada T, Noda S, Inui K (2015) Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 152:125–134

    CAS  Article  Google Scholar 

  9. 9.

    Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K et al (2015) Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 13:350–358

    Article  Google Scholar 

  10. 10.

    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300

    CAS  Article  Google Scholar 

  11. 11.

    Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762

    Article  Google Scholar 

  12. 12.

    Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60

    CAS  Article  Google Scholar 

  13. 13.

    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S et al (2014) Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Dis 32:705–710

    Article  Google Scholar 

  14. 14.

    Noda S, Shioya M, Hira D, Fujiyama Y, Morita SY, Terada T (2013) Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol 72:269–272

    CAS  Article  Google Scholar 

  15. 15.

    Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S (2016) Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res 46:951–963

    Article  Google Scholar 

  16. 16.

    Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M et al (2012) Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 17:1204–1212

    Article  Google Scholar 

  17. 17.

    Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O et al (2012) Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 7:e42875

    CAS  Article  Google Scholar 

  18. 18.

    Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7:e37563

    CAS  Article  Google Scholar 

  19. 19.

    Kudo M (2017) Molecular targeted agents for hepatocellular carcinoma: Current status and future perspectives. Liver Cancer 6:101–112

    CAS  Article  Google Scholar 

  20. 20.

    Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66

    CAS  Article  Google Scholar 

  21. 21.

    Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M et al (2018) Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Investig New Drugs 36:332–339

    Article  Google Scholar 

  22. 22.

    Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y et al (2018) Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 48:814–820

    CAS  Article  Google Scholar 

  23. 23.

    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858

    CAS  Article  Google Scholar 

  24. 24.

    Goto H, Kitagawa N, Sekiguchi H, Miyagi Y, Keino D, Sugiyama M et al (2017) The Collagen gel droplet-embedded culture drug sensitivity test in relapsed hepatoblastoma. J Pediatr Hematol Oncol 39:395–401

    CAS  Article  Google Scholar 

  25. 25.

    Fukudo M, Ito T, Mizuno T, Shinsako K, Hatano E, Uemoto S et al (2014) Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 53:185–196

    CAS  Article  Google Scholar 

Download references

Acknowledgements

First of all, we thank all the patients that were willing to participate in this study. Furthermore, we would like to thank the hospital staff in acquiring the data.

Funding

This work was supported in part by grants from JSPS KAKENHI (Grant Numbers-JP18H00400), from the Research Foundation for Pharmaceutical Science, and from the Nakatomi Foundation.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Satoshi Noda.

Ethics declarations

Conflict of interest

All authors declare no conflict of interest that might be relevant to the contents of this manuscript.

Ethical approval

This study protocol was approved by the Institutional Review Board of Shiga University of Medical Science. All patients gave written informed consent for the use of their blood sample and medical information for research.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Noda, S., Hira, D., Osaki, R. et al. Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study. Cancer Chemother Pharmacol 86, 129–139 (2020). https://doi.org/10.1007/s00280-020-04105-0

Download citation

Keywords

  • Sorafenib
  • Hepatocellular carcinoma
  • Pharmacokinetics
  • Personalized pharmacotherapy